(888) 552-6760 SCHEDULE A CONSULTATION
Clinical-Trials

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

34 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The primary objective of this study for the safety run-in cohorts of the study is to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with nab-paclitaxel or paclitaxel (safety run-in cohort 1), and sacituzumab govitecan (safety run-in cohort 2) in metastatic triple-negative breast cancer (mTNBC).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

An open-label, randomized, phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab vs. chemotherapy in the second-line treatment setting in patients with colorectal cancer with KRAS G12C mutation.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

A phase 2 study of magrolimab combination therapy in patients with head and neck squamous cell carcinoma

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study will be a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior TKI.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase 2 multicenter, open-label study evaluating the efficacy, safety, tolerability, and pharmacokinetics (PK) of RMC-4630 in combination with sotorasib in subjects with KRASG12C mutant NSCLC after failure of prior standard therapies.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-naïve NSCLC patients.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a global phase 2, multi-center, single-arm, open label study of taletrectinib in patients of NSCLC harboring with ROS1 fusion gene.

   

Accepting new patients

 

Learn more at

clinicaltrials.gov

An open-label, phase 2 trial of nanatinostat in combination with valganciclovir in patients with Epstein-Barr virus-positive (EBV+) relapsed/refractory lymphomas.